NASDAQ · Financial Statements
Skye Bioscience, Inc. (SKYE) Financial Statements
$1.69
NASDAQ: SKYE
Market Cap $7.42M
Overview Financials Dividend Skye Bioscience, Inc. most recently reported annual revenue of $0, net profit of $-56.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-8.0M $-18.0M $-35.0M $-30.0M $-58.0M Net Profit $-9.0M $-19.0M $-38.0M $-27.0M $-56.0M EPS $-40.00 $-70.16 $-42.96 $-5.84 $-11.28 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $10.0M $9.0M $12.0M $73.0M $28.0M Total Liabilities $4.0M $12.0M $14.0M $5.0M $8.0M Cash $9.0M $1.0M $1.0M $68.0M $6.0M Borrowings $2.0M $2.0M $5.0M $0 $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-6.0M $-13.0M $-14.0M $-25.0M $-43.0M Investing Cash Flow $0 $5.0M $7.0M $-2.0M $-20.0M Financing Cash Flow $7.0M $0 $0 $0 $0 Net Cash Flow $7.0M $-8.0M $9.0M $58.0M $-63.0M Free Cash Flow $-7.0M $-13.0M $-14.0M $-27.0M $-43.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.01 EV / EBITDA 0.01 FCF Yield -525.87% Quick Ratio 0.95 Interest Coverage -9439.02 Return 1Y -83.79% Return 3Y -88.46% Return 5Y -98.53%
Screens featuring this stock